Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
Preeclampsia (PE) is a pregnancy-specific syndrome characterized by hypertension, proteinuria and edema, which resolves on placental delivery. It is thought to be the consequence of impaired placentation due to inadequate trophoblastic invasion of the maternal spiral arteries. In PE the maternal plasma concentration of free vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) is decreased whereas the concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and of soluble endoglin (sEng) is increased. These soluble receptors may bind VEGF, PLGF and TGFbeta1 and TGFbeta3 in the maternal circulation, causing endothelial dysfunction in many maternal tissues. Hence there is a view that the pathogenesis is more or less clarified. According to the vascular theory, poor placentation leads to poor uteroplacental perfusion and hypoxia, which stimulates sFlt-1 and sEng production causing the maternal syndrome. This assumption has been recently challenged. The role of hypoxia as the main stimulus for release of sFlt-1 has been questioned and the role of inflammatory mechanisms has been emphasized. According to this inflammatory theory, poor placentation may predispose more to placental oxidative stress than hypoxia and endothelial dysfunction may be part of a broader disorder of systemic inflammation. Finally, the recent demonstration of activating auto-antibodies to the angiotensin 1 receptor that experimentally play a major pathogenic role in PE further suggests a pleiotropism of aetiologies for this condition. The purpose of this review is to critically evaluate the recent hypotheses and their possible insights on early diagnosis, prevention and treatment.
University of Liege, Department of Obstetrics and Gynaecology, Hospital de la Citadelle, Blvd du XII(eme) de Ligne, 4000 Liege, Belgium. jmfoidart@ulg.ac.be
J M
JM
Foidart
J P
JP
Schaaps
F
F
Chantraine
C
C
Munaut
S
S
Lorquet
D020533:Angiogenesis Inhibitors / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D000071063:Endoglin; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000276:immunology; D010920:Placenta / Q000098:blood supply / Q000276:immunology*; D000072483:Placenta Growth Factor; D010929:Placentation; D011225:Pre-Eclampsia / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000276:immunology; D044140:Receptor, Angiotensin, Type 1 / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000276:immunology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000276:immunology
D020533:Angiogenesis Inhibitors; D015703:Antigens, CD; D001323:Autoantibodies; C064206:ENG protein, human; D000071063:Endoglin; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D044140:Receptor, Angiotensin, Type 1; D011956:Receptors, Cell Surface; D000072483:Placenta Growth Factor; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1